Last edition
News about "Oncolytics Biotech COVID-19 pandemic"
Oncolytics Biotech updates clinical development & operations activities during COVID-19 pandemic
Oncolytics Biotech Inc., currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, provided an update on the potential impact of COVID-19 on the company's clinical and business operations
Oncolytics Biotech COVID-19 Pandemic | 20/04/2020 | By Darshana | 292
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members